Genmab A/S
CSE:GMAB
Genmab A/S
Cash Interest Paid
Genmab A/S
Cash Interest Paid Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Interest Paid | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Genmab A/S
CSE:GMAB
|
Cash Interest Paid
kr35m
|
CAGR 3-Years
43%
|
CAGR 5-Years
12%
|
CAGR 10-Years
80%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Cash Interest Paid
kr24m
|
CAGR 3-Years
94%
|
CAGR 5-Years
48%
|
CAGR 10-Years
28%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Cash Interest Paid
€15.2m
|
CAGR 3-Years
102%
|
CAGR 5-Years
84%
|
CAGR 10-Years
N/A
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Cash Interest Paid
kr32.2m
|
CAGR 3-Years
10%
|
CAGR 5-Years
11%
|
CAGR 10-Years
23%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Cash Interest Paid
kr381k
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
13%
|
|
|
Saniona AB
STO:SANION
|
Cash Interest Paid
kr5.9m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
65%
|
CAGR 10-Years
65%
|
|
Genmab A/S
Glance View
In the world of biotechnology, Genmab A/S has carved a niche as a leader in the development and innovation of antibody therapeutics. Established in Denmark in 1999, the company has focused on harnessing the power of antibodies to create novel treatments for cancer and other serious diseases. Genmab's approach is both scientific and strategic, leveraging its proprietary DuoBody and HexaBody platforms to engineer antibodies that are designed to enhance effectiveness and reduce side effects. This innovative focus has not only set Genmab apart as a pioneer in immunotherapy but has also yielded a rich pipeline of products, several of which have gained regulatory approval and found a place in global markets. Genmab's business model is built on a foundation of collaboration and strategic partnerships with major pharmaceutical companies, including heavyweights such as Janssen and Roche. These alliances are crucial as they provide the financial support needed for large-scale clinical trials and access to global distribution networks. Revenue streams primarily flow from milestone payments, licensing fees, and royalties generated from successful therapies. The company's notable blockbuster, Darzalex, a treatment for multiple myeloma, continues to be a significant revenue driver, exemplifying Genmab's capacity to transform scientific discovery into economic success. Through this blend of innovation, strategic partnerships, and commercialization, Genmab maintains a robust business while keeping its dedication to pioneering treatments at the forefront of its mission.
See Also
What is Genmab A/S's Cash Interest Paid?
Cash Interest Paid
35m
DKK
Based on the financial report for Dec 31, 2024, Genmab A/S's Cash Interest Paid amounts to 35m DKK.
What is Genmab A/S's Cash Interest Paid growth rate?
Cash Interest Paid CAGR 10Y
80%
Over the last year, the Cash Interest Paid growth was 40%. The average annual Cash Interest Paid growth rates for Genmab A/S have been 43% over the past three years , 12% over the past five years , and 80% over the past ten years .
You don't have any saved screeners yet